Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
NEW YORK, Dec. 07, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Centene Corp. (“Centene”) (NYSE:CNC) between April 26, 2016 and September 6, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. If you purchased or otherwise acquired Centene securities between April 26, 2016 and September 6, 2016, your rights may be affected by this action. To get more information go to:
http://www.zlk.com/pslra/centene-corp
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Centene made materially false and misleading statements concerning the acquisition of Health Net, Inc. and failed to disclose: (1) that certain Health Net insurance programs were significantly underperforming, which led to the need to increase reserves to offset losses caused by these programs; (2) that Centene overstated the financial prospects of Health Net; and (3) that as a result of the above, the Company’s statements concerning its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Centene you have until January 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
